Icosapent Ethyl
- Generic Name
- Icosapent Ethyl
- Brand Names
- Vascepa, Vazkepa
- Drug Type
- Small Molecule
- Chemical Formula
- C22H34O2
- CAS Number
- 86227-47-6
- Unique Ingredient Identifier
- 6GC8A4PAYH
- Background
Icosapent ethyl or ethyl eicosapentaenoic acid is a synthetic derivative of the omega-3 fatty acid eicosapentaenoic acid (EPA). It is used as an adjunct therapy for severe hypertriglyceridemia (TG levels > 500 mg/dL) and to reduce the risk of cardiovascular events in certain patients with elevated triglycerides. FDA approved on July 26, 2012.
- Indication
作为最大耐受他汀类药物治疗的辅助手段，以降低甘油三酯（TG）水平升高（≥150mg/dL）、已确定的心血管疾病或糖尿病以及2个或更多心血管疾病风险因素的成年患者需要住院治疗的心肌梗死、中风、冠状动脉血运重建和不稳定心绞痛的风险。
- Associated Conditions
- Hospitalizations, Severe Hypertriglyceridemias
Effects of Eicosapentaenoic Acid on Endothelial Function in Diabetic Subjects
- First Posted Date
- 2015-04-21
- Last Posted Date
- 2022-03-18
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 2
- Registration Number
- NCT02422446
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin
- Conditions
- Cardiovascular Diseases
- Interventions
- First Posted Date
- 2011-12-15
- Last Posted Date
- 2022-04-14
- Lead Sponsor
- Amarin Pharma Inc.
- Target Recruit Count
- 8179
- Registration Number
- NCT01492361
- Locations
- 🇺🇦
Amarin Investigational Site, Zaporizhzhia, Ukraine
Eicosapentaenoic Acid Cerebral Vasospasm Therapy Study
- Conditions
- Subarachnoid HemorrhageCerebral Vasospasm
- Interventions
- First Posted Date
- 2009-02-09
- Last Posted Date
- 2009-09-03
- Lead Sponsor
- Yamaguchi University Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT00839449
- Locations
- 🇯🇵
Iwate Medical University, Morioka, Iwate, Japan
🇯🇵Yamaguchi University Hospital, Ube, Yamaguchi, Japan
🇯🇵Ootemachi Hospital, Kitakyushu, Fukuoka, Japan
Ethyl-EPA Treatment of Prodromal Patients
- First Posted Date
- 2008-03-13
- Last Posted Date
- 2014-05-22
- Lead Sponsor
- Yale University
- Target Recruit Count
- 7
- Registration Number
- NCT00634361
TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease
- Conditions
- Huntington Disease
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2007-12-27
- Lead Sponsor
- Amarin Neuroscience Ltd
- Target Recruit Count
- 300
- Registration Number
- NCT00146211
- Locations
- 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸University of Pittsburgh, Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.